Project Grant R41CA261420
- Federal Project Grant Award Summary Navigation Sciences Inc. received a $225,229 Project Grant award on September 19, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop EndonaviSci, an advanced navigation software system designed to improve lung cancer surgical outcomes. The software will address critical clinical challenges in performing segmentectomy—a lung-preserving surgical procedure—by enabling accurate localization...
- This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
- Grant Award Summary Safeguard Surgical, Inc. received a $1.22 million Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 18, 2025, with completion targeted for August 31, 2027. The project develops and validates LeakGuard, a biodegradable barrier device designed to prevent anastomotic leakage (AL)—a serious complication affecting up to 22% of esophageal cancer patients...
- This Project Grant award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, supports the development and validation of a novel, projection-based surgical navigation platform by Illuminant Surgical Inc. The $274,865 award, effective January 15, 2024, aims to create a system that projects visual anatomical references and guidance directly onto a patient's skin during minimally invasive spinal procedures. This is expected to...
- Smartairway LLC received a Project Grant award of $313,365 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period of August 1, 2025 through July 31, 2027. The company is developing the SmartStylet, an innovative articulating stylet device designed to improve first-pass endotracheal intubation (ETI) success rates during surgical procedures and emergency medical interventions. The device utilizes a uniquely...
- This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
- Summary of Federal Project Grant Award Brigham & Women's Hospital Inc. received a $1.554 million Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a trackerless surgical navigation system for minimally invasive liver surgery. The award, dated August 1, 2025, with performance extending through July 31, 2029, funds the...
- Federal Grant Award Summary Illuminant Surgical Inc. received a $1,107,943 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on September 12, 2025, with a completion date of August 31, 2027. This Phase II effort focuses on the continued development and validation of Skylight, a mixed-reality navigation platform designed to improve the accuracy and safety of image-guided biopsy procedures. The platform employs advanced...
- Federal Grant Award Summary On October 1, 2025, the National Science Foundation (NSF) awarded $305,000 to Bullseye Biodevices, Inc. under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) for a Small Business Technology Transfer (STTR) Phase I project focused on developing a novel biosensing device for intraoperative tumor margin detection. The award funds the design, development, and in situ validation of an electromechanical probe system integrated with robotic...
- Federal Project Grant Award Summary Georgia TECH Research Corp received a $416,231 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded May 1, 2026, with completion scheduled for April 30, 2028. The grant funds development of a robotically steerable bronchoalveolar lavage (RoboBAL) device designed to improve diagnostic yield for pulmonary complications in critically ill children. The project addresses the significant clinical limitation that...
BRONCHOSCOPIC LUNG NAVIGATION SYSTEM FOR ACCURATELY EXCISING LUNG NODULES - ABSTRACT THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP AND COMMERCIALIZE A NAVIGATION SYSTEM THAT CAN ACCURATELY DETERMINE MARGINS IN REAL-TIME DURING SURGERY FOR LUNG CANCER. SURGERY IS CURRENTLY THE STANDARD OF CARE FOR EARLY STAGE LUNG CANCER. A CRITICAL CHALLENGE IS TO RELIABLY IDENTIFY SMALL, EARLY-STAGE TUMORS AND RESECT THEM WITH SUFFICIENT MARGINS (DISTANCE BETWEEN THE EDGE OF TUMOR AND THE LINE OF RESECTION). TOO CLOSE A MARGIN IS ASSOCIATED WITH A HIGHER INCIDENCE OF RECURRENCE AND DEATH. TO ADDRESS THIS CHALLENGE, THIS TEAM DEVELOPED A NEW SURGICAL PROCEDURE CALLED IMAGE-GUIDED VIDEO THORACOSCOPIC SURGERY (IVATS), IN WHICH THE SURGEON LOCALIZES AND RESECTS SMALL LUNG NODULES BY MARKING THEM PERCUTANEOUSLY USING A FIDUCIAL MARKER, A SMALL PASSIVE METAL TAG CALLED T-BAR, PLACED UNDER C-ARM CT IMAGE-GUIDANCE. A NOVEL NAVIGATION TECHNOLOGY, NAVISCI, WAS DEVELOPED TO AID IN IDENTIFYING AND REMOVING LUNG TUMORS BY USING AN ACTIVE SENSING NODULE MARKER, CALLED J- BAR, THAT IS PLACED IN THE LUNG JUST NEXT TO THE TUMOR AND CAN TRACK THE TUMOR POSITION IN REAL-TIME AND HELP ASSESS MARGINS. HOWEVER, USE OF THE J-BAR REQUIRES EITHER INTRAOPERATIVE IMAGING OR APPROXIMATE VISUAL POSITIONING OF VERY SMALL TUMORS THAT MAY NOT BE VISIBLE DURING SURGERY FROM THE LUNG SURFACE. NAVIGATION SCIENCES IS NOW DEVELOPING A TUMOR MARKER THAT CAN BE POSITIONED WITH A BRONCHOSCOPE AND DOES NOT REQUIRE CT IMAGING DURING SURGERY. THE OBJECTIVE OF THIS PHASE I STTR PROJECT IS TO DEVELOP AND VALIDATE THE NAVISCI-ENDOMARKERTM (CALLED ENDOMARKER HEREAFTER) TO ACCURATELY LOCALIZE SMALL LUNG TUMORS. THE ENDOMARKER WILL BE POSITIONED ADJACENT TO THE TUMOR WITH A BRONCHOSCOPE BASED ON NAVIGATION PLANNED USING DIAGNOSTIC CT IMAGES. THIS WILL SIMPLIFY THE CLINICAL WORKFLOW AND MAKE THIS PROCEDURE ACCESSIBLE TO HOSPITALS THAT DO NOT HAVE ADVANCED INTRA-OPERATIVE IMAGING TECHNOLOGIES. AIM 1 IS TO DESIGN AND DEVELOP THE BRONCHOSCOPIC ENDOMARKER. AIM 2 IS TO VALIDATE THE WORKFLOW FOR DEPLOYING THE ENDOMARKER, MECHANICAL STABILITY, AND ELECTRICAL ISOLATION OF THE ENDOMARKER IN A 3D PRINTED LUNG PHANTOM, EX VIVO PORCINE LUNGS AND 2 LIVE PIGS. THIS STTR PROJECT IS A COLLABORATION BETWEEN NAVIGATION SCIENCES AND ONGOING COLLABORATORS AT THE BRIGHAM AND WOMEN'S HOSPITAL (BOSTON, MA). THE PROPOSED R & D PROJECT IS SIGNIFICANT SINCE IT ADDRESSES AN IMPORTANT PROBLEM OF ACCURATELY LOCALIZING AND RESECTING LUNG NODULES WHILE PRESERVING HEALTHY LUNG FUNCTION, WHICH COULD BENEFIT THOUSANDS OF PATIENTS EACH YEAR. THE NOVELTY LIES IN THE DESIGN OF THE ENDOMARKER, WHICH WILL ALLOW THE J-BAR MARKER TO BE PLACED ACCURATELY VIA A BRONCHOSCOPE SO THAT IT CAN READILY LOCALIZE SMALL TUMORS AND DEFINE THEIR MARGINS DURING SURGERY. SUCCESSFUL COMPLETION OF THIS PROJECT WILL RESULT IN AN INNOVATIVE DISRUPTIVE PRODUCT THAT WILL PROVIDE SURGICAL GUIDANCE TO ENSURE SUFFICIENT RESECTION OF EARLY-STAGE LUNG CANCER WITH ACCEPTABLE MARGINS WITHOUT ANY ADDITIONAL IMAGING EQUIPMENT AT THE MEDICAL CENTER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/15/24 | ||
| Not listed | $0 | 12/27/22 | ||
| Not listed | $0 | 12/27/22 | ||
| Not listed | $0 | 12/27/22 | ||
| Not listed | $76.0k | 8/25/22 |